SCHEMBL7657048

SCHEMBL7657048

CSc1ccc(C(=O)Nc2ccc(/C=C/c3ccccc3NC(=O)c3ccc(SC)c(S(=O)(=O)N4CCOCC4)c3)c(S(=O)(=O)O)c2)cc1S(=O)(=O)N1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.52
SMN1; SMN2 Q16637 7/20 0.52
MAPK1 P28482 5/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
MAPT P10636 2/20 0.52
USP2 O75604 2/20 0.52
CNR1 P21554 2/20 0.49
CNR2 P34972 1/20 0.49
TSHR P16473 5/20 0.49
NPC1 O15118 2/20 0.49
HSD17B10 Q99714 2/20 0.49
ALDH1A1 P00352 7/20 0.48
GAA P10253 3/20 0.48
KDM4E B2RXH2 2/20 0.48
TP53 P04637 3/20 0.48
POLB P06746 1/20 0.48
HTT P42858 1/20 0.48
HPGD P15428 1/20 0.47
OPRM1 P35372 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7657065 1.00 LMNA (0.52) LMNASMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL7661298 0.93 SMN1; SMN2 (0.56) LMNASMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL7661372 0.93 SMN1; SMN2 (0.56) LMNASMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL7657079 0.90 LMNA (0.52) LMNASMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL7663003 0.86 LMNA (0.52) LMNASMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL7663114 0.86 LMNA (0.52) LMNASMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL7658971 0.84 CNR2 (0.53) LMNASMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL7659042 0.84 CNR2 (0.53) LMNASMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL7659521 0.83 MAPT (0.54) LMNASMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL7659541 0.83 MAPT (0.54) LMNASMN1; SMN2MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-08-15 US claimed
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-08-15 US disclosed
US-6355633-B1 CONTRACEPTIVES AMERICAN HOME PRODUCTS CORPORATION 2002-03-12 US disclosed
WO-2000058277-A1 ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists FSHR, GNRHR, LHCGR LMNA 3330/4885SMN1; SMN2 2927/4885MAPK1 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.